CR Pharmaceutical subsidiaries report Q1 2025 results; bond issuance complete

China Resources Pharmaceutical Group (HKEX:3320) announced first quarter 2025 financial results for several of its key subsidiaries and the completion of a new bond issuance. Dong-E-E-Jiao reported unaudited revenue of RMB1.71 billion and net profit of RMB425 million for the three months ended March 31, 2025, alongside Jiangzhong Pharmaceutical, which recorded revenue of RMB1.18 billion with net profit of RMB306 million for the same period. CR Double-Crane posted revenue of RMB3.07 billion and net profit of RMB522 million. CR Boya Bio-pharmaceutical reported revenue of RMB535 million with a net profit of RMB139 million.